Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 19, 2021
Markolf Hanefeld, Michael Zitzmann, Eberhard Nieschlag
Expert Opinion on Drug Metabolism & Toxicology|November 4, 2016
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitusMarkolf Hanefeld, Denis Raccah, Louis Monnier
Clinical Laboratory|April 6, 2002
Oral glucose tolerance test: to be or not to be performed?Theodora S Temelkova-Kurktschiev, Markolf Hanefeld
Cardiovascular Drugs and Therapy|March 1, 2008
Effect of acarbose on vascular disease in patients with abnormal glucose toleranceMarkolf Hanefeld, Frank Schaper, Carsta Koehler
Expert Opinion on Pharmacotherapy|June 7, 2011
Review of approved pioglitazone combinations for type 2 diabetesThomas Forst, Markolf Hanefeld, Andreas Pfützner
Cardiovascular Diabetology|September 24, 2013
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewMarkolf Hanefeld, Eva Duetting, Peter Bramlage
Diabetes Care|July 22, 2016
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?Markolf Hanefeld, Brian M Frier, Frank Pistrosch
Diabetes, Obesity & Metabolism|May 6, 2017
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitusDavid R Owens, Louis Monnier, Markolf Hanefeld
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|December 19, 2006
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetesMarkolf Hanefeld, Rita Patwardhan, Nigel P Jones, et al.
Diabetes Care|October 31, 2009
Shifting the disease management paradigm from glucose: what are the cons?Markolf Hanefeld, Stefan R Bornstein, Frank Pistrosch
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Deutsche Medizinische Wochenschrift (1946)|May 19, 2021
Markolf Hanefeld, Michael Zitzmann, Eberhard Nieschlag
Expert Opinion on Drug Metabolism & Toxicology|November 4, 2016
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitusMarkolf Hanefeld, Denis Raccah, Louis Monnier
Clinical Laboratory|April 6, 2002
Oral glucose tolerance test: to be or not to be performed?Theodora S Temelkova-Kurktschiev, Markolf Hanefeld
Cardiovascular Drugs and Therapy|March 1, 2008
Effect of acarbose on vascular disease in patients with abnormal glucose toleranceMarkolf Hanefeld, Frank Schaper, Carsta Koehler
Expert Opinion on Pharmacotherapy|June 7, 2011
Review of approved pioglitazone combinations for type 2 diabetesThomas Forst, Markolf Hanefeld, Andreas Pfützner
Cardiovascular Diabetology|September 24, 2013
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic reviewMarkolf Hanefeld, Eva Duetting, Peter Bramlage
Diabetes Care|July 22, 2016
Hypoglycemia and Cardiovascular Risk: Is There a Major Link?Markolf Hanefeld, Brian M Frier, Frank Pistrosch
Diabetes, Obesity & Metabolism|May 6, 2017
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitusDavid R Owens, Louis Monnier, Markolf Hanefeld
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|December 19, 2006
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetesMarkolf Hanefeld, Rita Patwardhan, Nigel P Jones, et al.
Diabetes Care|October 31, 2009
Shifting the disease management paradigm from glucose: what are the cons?Markolf Hanefeld, Stefan R Bornstein, Frank Pistrosch
Pageof 13